AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase I/II study titled ‘ATHENA’ to evaluate the safety and efficacy of AZD5851, a CAR-T cell therapy, in adults with advanced or recurrent hepatocellular carcinoma (HCC) that expresses GPC3. This study is significant as it targets a specific protein, GPC3, which is prevalent in HCC, aiming to provide a new treatment avenue for patients who have not responded to previous therapies.
The intervention involves AZD5851, a biological treatment where patients undergo leukapheresis to produce the CAR-T cells, followed by lymphodepleting chemotherapy and a single dose of AZD5851 via IV infusion. This approach is designed to enhance the body’s immune response against cancer cells.
The study follows an open-label, single-group design with no masking, focusing on treatment as the primary purpose. This structure allows for direct observation of the treatment’s effects on participants.
Key dates include the actual start date of December 14, 2023, with the latest update submitted on August 12, 2025. These timelines are crucial for tracking the study’s progress and anticipating results.
The market implications of this study are significant for AstraZeneca’s stock performance, as successful outcomes could enhance investor confidence and position the company as a leader in innovative cancer therapies. This could also influence the competitive landscape, prompting responses from other players in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.